Delaying LPN Okay for Small Renal Tumors

Share this article:
Delaying laparoscopic partial nephrectomy (LPN) for patients with small renal masses has no significant effect on oncologic and perioperative outcomes, according to study findings published in BJU International (2009;103:1355-1358).

The study, led by Mohamad E. Allaf, MD, of Johns Hopkins' James Buchanan Brady Urological Institute in Baltimore, included 32 patients who underwent LPN for T1a renal masses after a mean surveillance period of 15.8 months. Researchers compared this group with a matched group of patients who underwent immediate LPN.

Participating patients had a mean tumor size of about 2 cm. Tumor growth rate in the surveillance group was 0.56 cm per year. Benign and malignant tumors had similar growth rates.

The groups were similar with respect to warm ischemia time, operating room time, complications, postoperative length of hospital stay, and in the proportion of patients upstaged from cT1 to pT3a. After a mean follow-up of 60 months, no local recurrences or distant metastases occurred in either group.

The researchers concluded that a treatment delay of more than one year was not associated with additional surgical morbidity or inferior oncologic outcomes.
Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Kidney Cancer

More in Kidney Cancer

Partial Nephrectomy Superior Despite Kidney Tumor Size

Partial Nephrectomy Superior Despite Kidney Tumor Size

Renal function is preserved better compared with radical nephrectomy even when tumors are larger than the traditional 4 cm cutoff.

Renal Tumor Risk Higher in Lithium-Treated Patients

Renal Tumor Risk Higher in Lithium-Treated Patients

Renal tumors occur at a frequency 7.5 times greater in lithium-treated patients than in the general population, French study shows.

High Cholesterol Predicts Better RCC Outcomes

High Cholesterol Predicts Better RCC Outcomes

Patients with levels of 161.5 mg/dL or greater had a 43% decreased risk of death from renal cell carcinoma than those with lower levels.